Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

Documenti analoghi

• Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
  di: Hans Johnson, et al.
  Pubblicazione: (2025)
• Comparing Apples to Oranges: A comparison on Efficacy data for monoclonal antibodies and cholinesterase inhibitors for treatment of Alzheimer’s Disease from FDA Medical and Statistical Reports
  di: Aishwarya Prasad, et al.
  Pubblicazione: (2025)
• Insulin requirements after switching from GLP ‐1 receptor agonist to dual GIP / GLP ‐1 receptor agonist in patients with type 2 diabetes mellitus
  di: Alexa M. Lahey, et al.
  Pubblicazione: (2025)
• Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
  di: Lien‐Chung Wei, et al.
  Pubblicazione: (2025)
• The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study
  di: Yuxin Fan, et al.
  Pubblicazione: (2025)